Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist | Zendy

Jamo Hoekman | Zendy; Hiddo J.L. Heerspink | Zendy; Giancarlo Viberti | Zendy; Damien Green | Zendy; Johannes F.E. Mann | Zendy; Dick de Zeeuw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist

Author(s) -

Jamo Hoekman,

Hiddo J.L. Heerspink,

Giancarlo Viberti,

Damien Green,

Johannes F.E. Mann,

Dick de Zeeuw

Publication year - 2014

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.07040713

Subject(s) - medicine , interquartile range , heart failure , cardiology , hazard ratio , creatinine , confidence interval

The Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death (ASCEND) trial tested the renoprotective effect of the endothelin receptor antagonist avosentan in patients with diabetes and nephropathy, but the study was terminated due to an excess of congestive heart failure (CHF) events in the avosentan arms, likely due to fluid retention. The aim of this study was to identify risk markers of CHF after treatment with avosentan.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research